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Malaria  transmission  blocking  (TB) vaccines  (TBVs)  directed  against  proteins  expressed  on the  sexual
stages  of  Plasmodium  parasites  are a potentially  effective  means  to reduce  transmission.  Antibodies
induced  by  TBVs  block  parasite  development  in  the mosquito,  and  thus  inhibit  transmission  to fur-
ther  human  hosts.  The  ookinete  surface  protein  P25  is  a  primary  target  for TBV development.  Recently,
transient  expression  in  plants  using  hybrid  viral  vectors  has  demonstrated  potential  as a strategy  for  cost-
effective  and  scalable  production  of  recombinant  vaccines.  Using  a plant  virus-based  expression  system,
we produced  recombinant  P25  protein  of  Plasmodium  vivax  (Pvs25)  in Nicotiana  benthamiana  fused to a
modiﬁed  lichenase  carrier  protein.  This  candidate  vaccine,  Pvs25-FhCMB,  was  puriﬁed,  characterized  and
evaluated  for  immunogenicity  and  efﬁcacy  using  multiple  adjuvants  in  a transgenic  rodent  model.  An
in  vivo  TB  effect  of up  to a 65%  reduction  in  intensity  and  54%  reduction  in  prevalence  was  observed  using
Abisco-100  adjuvant.  The  ability  of this  immunogen  to induce  a TB  response  was additionally  combined
with  heterologous  prime-boost  vaccination  with  viral  vectors  expressing  Pvs25.  Signiﬁcant  blockade  was
observed  when  combining  both  platforms,  achieving  a 74% and  68%  reduction  in  intensity  and  prevalence,
respectively.  This  observation  was  conﬁrmed  by  direct  membrane  feeding  on  ﬁeld P. vivax  samples,  result-
ing in  reductions  in intensity/prevalence  of 85.3%  and  25.5%.  These  data  demonstrate  the  potential  of  this
vaccine  candidate  and  support  the  feasibility  of  expressing  Plasmodium  antigens  in  a  plant-based  system
for the  production  of  TBVs,  while  demonstrating  the potential  advantages  of combining  multiple  vaccine
delivery  systems  to maximize  efﬁcacy.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC BY  license. Introduction
Malaria is a global disease caused by parasites of the genus Plas-
odium. An estimated 207 million cases of malaria are reported
nnually, causing approximately 627,000 deaths [1,2]. Of the ﬁve
pecies of malaria parasites that infect humans, Plasmodium falcip-
rum and Plasmodium vivax lead to the greatest burden of disease.
hile P. falciparum is responsible for the majority of malaria-linked
eaths, P. vivax can cause relapses months after the ﬁrst infection
∗ Corresponding author. Tel.: +44 0207594 5350.
E-mail address: andrew.blagborough@imperial.ac.uk (A.M. Blagborough).
ttp://dx.doi.org/10.1016/j.vaccine.2016.05.007
264-410X/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article(http://creativecommons.org/licenses/by/4.0/).
[4] caused by hypnozoites, and require specialized treatment, e.g.
primaquine [2–4]. P. vivax is the most widely distributed human
malaria parasite, with 2.5 billion people at risk of infection, and
80−300 million cases per annum [1,3]. Multiple factors, including
the appearance of chloroquine-resistant P. vivax [5], lack of prac-
tical alternatives to primaquine, combined with increasing global
temperatures [6,7], have raised concerns related to increased risks
of P. vivax-induced disease.
No licensed vaccine for malarial prophylaxis is currently
available [8,9]. Chemotherapy is the only clinically available treat-
ment for conﬁrmed infection; however, recurring drug resistance
reduces the efﬁciency of anti-malarials [4]. The importance of vac-
cines against P. vivax is well understood, but a lack of long-term
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.5. Immunization regimesA.M. Blagborough et al. /
n vitro culture systems and suitable animal models have hindered
evelopmental advances.
Malaria transmission-blocking (TB) vaccines (TBVs) show
romise as a method to reduce transmission. Brieﬂy, antibod-
es produced within an individual in response to vaccination
re ingested by the mosquito along with gametocytes, during a
loodmeal. These antibodies prevent parasite development in the
osquito midgut by binding to surface proteins of the sexual
tages, impeding further transmission [10,11]. One of the primary
argets for TBV development is the P25 protein, expressed predom-
nantly on the surface of the Plasmodium zygote and ookinete [12].
25 is characterized by the presence of epidermal growth factor
EGF)-like motifs, multiple cysteine residues and a complex ter-
iary structure [13], making it challenging to produce recombinant
rotein with appropriate conformation. Previous studies that have
uccessfully expressed P. vivax P25 (Pvs25) in native conformation
ave been limited to small-scale studies, with “classical” recombi-
ant expression systems [15–17] or using multiple viral delivery
ystems [18,19,39].
Previously, studies have examined the potential of utilizing
lants as a cost-effective and scalable platform for vaccine produc-
ion [20,21]. Nicotiana benthamiana has been used in conjunction
ith a hybrid plant virus vector-based expression system [22] to
roduce subunit vaccine candidates against inﬂuenza, plague and
nthrax [23–28]. In related studies, this system has produced sol-
ble versions of P. falciparum P25 (Pfs25), either as stand-alone
roteins or as fusions to the modiﬁed lichenase carrier molecule
LicKM). In mice and rabbits, fusion and non-fusion versions of
lant-produced Pfs25 elicited high titers of anti-Pfs25 antibodies
hen administered with Alhydrogel as an adjuvant. These anti-
odies demonstrated potent TB activity [29,30].
Here, a Pvs25-LicKM fusion protein (Pvs25-FhCMB) was pro-
uced using N. benthamiana as an expression host. We  examined
fﬁcacy of this candidate vaccine by performing a head-to-head
omparison of induced TB potency following mouse immunization
ith recombinant Pvs25-FhCMB in the presence of two clinically
elevant adjuvants: Alhydrogel, a common aluminium hydroxide
et gel suspension, and Abisco-100, a non-toxic saponin-based
djuvant, and compared these to immunization with a lead aden-
viral vaccine platform. Recently, the development of viral vectored
lood-stage malaria vaccines has shown that high-level antibody
esponses can be induced by the adenovirus in mice [31,32], rabbits
33,34] and rhesus macaques [35]. Studies on vaccine candidates
MA1 and MSP  have demonstrated that this regimen is safe and
mmunogenic [36,37]. Previous experiments involving immuniza-
ion of mice with adenovirus expressing Pfs25 or Pvs25 have led to
ntibodies exhibiting TB efﬁcacy [38,39,49].
We show that immunization of mice with Pvs25-FhCMB elicited
ffective Pvs25-speciﬁc humoral immune responses and signif-
cant TB activity. The ability of antiserum generated from each
mmunization regime to recognize native Pvs25 was examined by
mmunoﬂuorescence assay (IFA). TB activity was assessed in vivo,
sing a transgenic rodent malaria parasite P. berghei (Pvs25DR3)
xpressing Pvs25, enabling rapid, safe and cost-effective examina-
ion of anti-Pvs25 responses [18,19,40]. We  additionally examined
he beneﬁt of a heterologous prime/boost regimen by priming ani-
als with Pvs25-FhCMB followed by boosting with recombinant
himpanzee adenovirus expressing Pvs25 (ChAd63-Pvs25). Efﬁ-
acy was examined by direct feeding assay (DFA), and in direct
embrane feeding assay (DMFA) against P. vivax ﬁeld samples.
aximal efﬁcacy was observed when combining adenoviral and
lant-derived immunogens in a single regime. Our data indicate
hat Nicotiana-produced Pvs25 antigen can induce signiﬁcant TB
esponses in vivo and ex vivo, and that this technology could be used
s part of a successful TBV immunization regime, either alone, or
n combination with other delivery systems.e 34 (2016) 3252–3259 3253
2. Materials and methods
2.1. Pvs25-FhCMB cloning and expression
Pvs25 protein sequence corresponding to Ala23-Leu195 (NCBI
accession XP 001608460) was codon optimized for plants expres-
sion (GeneArt®, Germany). The sequence was fused to the
C-terminus of LicKM (NCBI accession number ABG78599) [22],
containing pathogen-related-protein 1a signal peptide (PR-1a)
[(NCBI accession BAA14220)] at the N-terminus, the hexa-histidine
(6xHis) tag and the endoplasmic reticulum retention signal at the
C-terminus, to yield Pvs25–FhCMB (Fig. 1a). The gene was cloned
into the TMV-based hybrid expression vector pGRD4 [22,27]. Vec-
tor was  introduced into Agrobacterium tumefaciens GV3101 by
electroporation, and vacuum inﬁltrated into leaves of six-week-
old hydroponically grown N. benthamiana as described previously
[22,27].
2.2. Pvs25-FhCMB protein puriﬁcation and characterization
N. benthamiana plants expressing Pvs25-FhCMB were harvested
at 6 dpi and stored at ≤-60 ◦C. Plants were homogenized, extracted
with Triton X-100 (0.5%), centrifuged (16,000 × g, 15 min, 4 ◦C)
and ﬁltrated (Sartopore 2, 0.45/0.2 m)  prior to loading onto IMAC
resin (Ni-Sepharose Fast-Flow, GE Healthcare). Proteins was eluted
and loaded onto a CaptoQ column (GE Healthcare). Eluted fraction
was concentrated 10-fold by centrifugation (Centricon-70, 30 kDa
MWCO) and aliquots were frozen at ≤-60 ◦C. LicKM was expressed
as described previously [29,30].
SDS-PAGE was  performed on a 10% acrylamide gel and
Coomassie stained. For Western blot, samples were blocked with
I-Block (Applied Biosystems). Blots were developed using anti-
4xHis mAb  (Qiagen). Protein concentration of Pvs25-FhCMB was
determined by UV−vis spectrometry using the denaturing method
of Edelhoch (1967) with the theoretical extinction coefﬁcient of
73,960 M−1 cm−1. Analytical size exclusion chromatography was
performed on a Zenix300 HPLC column (Sepax Technologies, Inc.).
2.3. Production of viral vector-based Pvs25 vaccines
Antigen sequence (excluding the glycosylphosphatidylinosi-
tol (GPI) anchor addition site), i.e. Ala23-Leu195 of Pvs25 (Sal I
strain), was obtained from the NCBI protein database, codon opti-
mized for expression in Homo sapiens (GeneArt®, Life Technologies,
Germany), and the predicted native signal peptide replaced with
the human tissue plasminogen activator signal peptide. Recombi-
nant ChAd63, MVA  vaccines and controls were generated [31,38,42]
.
2.4. Production of recombinant Pvs25 (r-Pvs25) protein
Pvs25 antigen sequence was codon optimized for expression
in Homo sapiens, subcloned into modiﬁed pENTR4-LPTOS TM [48]
plasmid between a tPA leader and an afﬁnity sequence encoding
a biotin-acceptor peptide and a hexahistidine tag. Plasmids were
transfected into 2 × 106 cells/mL HEK293E cells. Soluble recom-
binant protein (r-Pvs25) was  afﬁnity-puriﬁed using a HiTrap HP
nickel column (GE Healthcare, USA), followed by size exclusion
chromatography using a Superdex 200 pg gel ﬁltration column (GE
Healthcare, UK) and conﬁrmed by SDS-PAGE.Eighty mice (Female BALB/c, 6–8 weeks of age (Harlan, UK))
were divided into groups of 10 mice, each group used for an
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Fig. 1. Design, expression and puriﬁcation of Pvs25-FhCMB.
(a) Schematic representation of the Pvs25-FhCMB expression construct showing positions of the PR-1a leader sequence, LicKM carrier protein, Pvs25 antigen and C-terminal
6xHis tag and KDEL. (b) Western blot showing expression of Pvs25-FhCMB in unclariﬁed homogenate (H), soluble (S) and detergent-solubilized (dS) fractions. Molecular
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enatured, reducing conditions (1) or denatured, non-reducing conditions (2). Mole
00)  of puriﬁed Pvs25-FhCMB (200 g load).
ndividual immunization regime (Fig. 2). Regimes 1−4 were exper-
mental whereas regimes 5−8 were immunized (i.m.) with control
mmunogens.
In each group, ﬁve mice were challenged with Pvs25DR3 [40],
nd ﬁve were challenged with wild-type (WT) P. berghei (2.34).
ransmission blockade observed with 2.34 was considered non-
peciﬁc and not attributed to Pvs25 immunization.
For vaccination with Alhydrogel, 10 doses (50 L per mouse)
TMere prepared by combining 85 L of Alhydrogel containing
50 g of aluminium in Eppendorf tubes under aseptic conditions
ith 165 L of TRIS buffer (20 mM Tris, pH 7.4, 0.9% NaCl). After
5 min, 250 L of antigen solution was added to corresponding
ig. 2. Anti-Pvs25 immunization regimes. Groups of 10 mice received each vaccine reg
vs25DR3 to assess for Pvs25-speciﬁc TB effects, and ﬁve mice were challenged with P. berg
o  attempt to induce a Pvs25 response. In regimes 5−8, mice were immunized with carrieof Pvs25-FhCMB (2 g load) stained with Coomassie. Pvs25-FhCMB was  run under
eight markers (M)  are BenchMark standards (Invitrogen). (d) Analytical SEC (Zenix
tubes, which were vortexed and incubated for 1 h. For Abisco-100TM
adjuvant, recombinant protein was mixed with adjuvant, vortexed
for 10 s and injected immediately (5 L Abisco-100 per mouse in
total vaccination volume). Viral-vectored vaccines were prepared
in sterile, endotoxin-free PBS prior to immunization, with doses of
1 × 1010 viral particles of ChAd63 vaccines at week 0 and 1 × 107
plaque forming units of MVA  vaccines at week 8. Control mice were
immunized with ChAd63 and MVA  expressing GFP as an irrelevant
antigen in place of Pvs25 (Ad-MVA GFP) [42]. For regimens where
Pvs25-FhCMB protein was used for immunization and boost, sera
were collected at days 0, 21 and 42. When initial immunization was
performed with ChAd63, sera were collected at days 0, 56 and 70.
ime. In each individual regime, for DFA ﬁve mice were challenged with P. berghei
hei 2.34 to control for non-speciﬁc TB effects. In regimes 1−4, mice were immunized
r protein or empty vector controls. All immunizations were performed i.m.
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.6. ELISA
Sera from mice were collected by tail-bleed prior to boost and
hallenge. Nunc-Immuno Maxisorp 96-well plates (NUNC) were
oated with 100 ng recombinant protein (Pvs25FhCMB or r-Pvs25)
vernight. Test sera was incubated for 2 h followed by goat anti-
ouse IgG-AP secondary (Sigma), 1:3000. Plates were developed
sing pNPP and read at OD405 until end-point detection set for each
ntigen. For r-Pvs25 ELISA, control regime titres were subtracted
rom mean end-point titres. The cut-off for determining end-point
iter was the mean OD value for pre-immune sera + three times the
tandard deviation.
.7. Parasite maintenance and challenge/DFA
Routine maintenance of P. berghei was carried out as described
reviously [40,41].
Prior to challenge, mice were PHz treated, and 3 days later
nfected i.p. with 106 P. berghei ANKA 2.34 or P. berghei Pvs25DR3
19,40]. Three days post-infection, DFA was performed as described
n Blagborough et al. [19], with >50 Anopheles stephensi mosquitoes
llowed to feed on each mouse. Twelve days later, midguts were
issected, and oocyst prevalence and intensity recorded and inhi-
ition, these values were compared to intensity and prevalence in
ice immunized with appropriate controls.
.8. DMFA
Peripheral blood was  collected from P. vivax infected Thai vol-
nteer patients. Ninety microliter of pooled serum from mice
mmunized with ChAd63u-Pvs25/Pvs25-FhCMB boost (regime 4)
r mice immunized with ChAd63-GFP/LicKM boost (regime 8) were
ixed with 90 L of heat-inactivated AB serum from naive donors.
erum was mixed with P. vivax-infected blood cells (1:1 v/v ratio).
he mixture was placed in a membrane feeder, 37 ◦C and Anopheles
irus A mosquitoes (Bangkok colony, Armed Forces Research Insti-
ute of Medical Sciences) were allowed to feed for 30 min. Mosquito
aintenance and dissection were performed as described in Blag-
orough et al. [19]. Reductions in intensity and prevalence were
ssessed with respect to the relevant controls.
.9. IFA
The ability of harvested sera to recognize native Pvs25 was
ssessed by IFA on Pvs25DR3 ookinetes as described in Sinden et al.
41].
.10. Ethical statement
All procedures were performed in accordance with the UK Ani-
als (Scientiﬁc Procedures) Act (PPL 70/7185) and approved by
he Imperial College AWERB. The Ofﬁce of Laboratory Animal Wel-
are Assurance for Imperial College covers all Public Health Service
upported activities involving live vertebrates in the US (no. A5634-
1). Protocol for blood collection from Thai patients (protocol #
MEC-11-033) was approved by Ethical Committees from the Fac-
lty of Tropical Medicine, Mahidol University and Ministry of Public
ealth, Thailand.
.11. Statistical analysisStatistical analysis was performed using Graphpad Prism. For
FA and DMFA, signiﬁcance was assessed using Mann–Whitney U
to examine differences in intensity) and Fisher’s exact probability
to examine differences in prevalence). Parametric ELISA tests weree 34 (2016) 3252–3259 3255
assessed using t-test. P-values < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Expression, puriﬁcation and characterization of
Pvs25-FhCMB
Pvs25-FhCMB expression was evaluated by Western blot of clar-
iﬁed extract (Fig. 1b). Solubility was  examined using an anti-4xHis
mAb  by Western blot of total unclariﬁed protein homogenate (H),
total soluble protein (S) and total soluble protein extracted with
0.5% Triton X-100 (dS) (Fig. 1b). Densitometry analysis of Western
blots indicated that Pvs25-FhCMB was ∼100% soluble.
Pvs25-FhCMB was recovered to >90% purity of TP using a two-
column chromatography approach consisting of IMAC followed by
anion exchange chromatography (Capto Q). SDS-PAGE indicates a
single prominent band at approximately 55 kDa (Fig. 1c). When
Pfs25-FhCMB was  run in non-reducing buffer, a single band, migrat-
ing at a similar molecular weight is observed. Analysis by analytical
SEC indicates a single prominent peak eluting at a size equivalent
to a 45 kDa standard (Fig. 1d), in good agreement with the theoret-
ical molecular weight of 46.4 kDa. Both the non-reduced SDS-PAGE
and the single SEC peak indicate Pfs25-FhCMB is a non-aggregated,
monomeric protein.
3.2. Immunogenicity of Pvs25-FhCMB and induction of
target-speciﬁc antibodies
To examine immunogenicity, pre-boost and end-point sera
were analyzed by ELISA against recombinant Pvs25-FhCMB (com-
prising LicKM) following immunization as outlined in Fig. 2. Sera
were taken from individual mice (ﬁve per group) and analyzed for
Pvs25-FhCMB-speciﬁc responses. No antibody responses against
Pvs25-FhCMB were detected in day 0 sera.
Analysis of responses following Pvs25-based immunization
detected anti-Pvs25 antibody both pre- and post-boost for all
regimes tested, with higher end-point titers detected post-boost
(Fig. 3a). There was a signiﬁcant increase in titers following booster
immunizations in regimes 1, 2 and 4 (p < 0.05), with the most
pronounced increase detected in regime 4, and a non-signiﬁcant
increase in titers following boost in regime 3 (p = 0.145). The highest
mean titer was  observed in regime 1 (Pvs25-FhCMB + Abisco-100).
The lowest anti-Pvs25-FhCMB end-point titers were exhibited with
regime 3 (Pvs25-ChAd63 + MVA). Differences detected between
mean end-point titers from regimes 1, 2 and 4 were not statistically
signiﬁcant (p > 0.05). End-point titers resulting from immuniza-
tion with Pvs25-ChAd63/MVA (regime 3) were signiﬁcantly lower
than those detected in all other groups (compared to regime 1:
p < 0.0001; compared to 2 (p = 0.0163); compared to 4 (p = 0.0003).
To assess end-point response to Pvs25 per se,  as opposed to
Pvs25-LicKM conjugate, ELISA was carried out against recombinant
r-Pvs25 (Fig. 3b). The lowest mean end-point titers were observed
against serum from regime 2, whereas the highest was observed
from regime 4; however, differences detected between end-point
titers from all regimes were not statistically signiﬁcant (p > 0.05).
To conﬁrm the induction of Pvs25-speciﬁc antibodies that rec-
ognize native protein, we  performed IFA on P. berghei Pvs25DR3
ookinetes using pooled end-point serum. Speciﬁc-speciﬁc staining
was observed using sera from immunization regimes 1, 2, 3 and
4 (Fig. 3c), conﬁrming the ability of generated serum to recognize
native Pvs25. Staining was  not observed with sera from any regime
against WT  ookinetes, or with sera derived from control regimes
(i.e. regimes 5, 6, 7 and 8).
3256 A.M. Blagborough et al. / Vaccine 34 (2016) 3252–3259
Fig. 3. Induction of antibody following immunization with Pvs25-FhCMB. The ability of different immunization regimes to generate Pvs25-speciﬁc antibody responses was
tested  by ELISA against recombinant Pvs25-FhCMB and IFA against Pvs25DR3 ookinetes. (a) Pre-boost and end-point titers of anti-Pvs25-FhCMB in serum. Bars show mean
titers  from ﬁve mice. Light grey = pre-boost, dark grey = post-boost. Pre-immune serum did not recognize recombinant Pvs25-FhCMB. Error bars represent SEM. (b) End-point
titers  of anti-r-Pvs25 serum. Bars show mean titers from ﬁve mice. Error bars represent SEM. (c) IFA against Pvs25DR3 ookinetes. Ability of generated serum to recognize
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ith  DAPI (blue). IFA with non-Pvs25 derived (control) serum from regimes 5−8 re
.3. Evaluation of in vivo TB activity (DFA)
For examination of transmission blockade in vivo, ﬁve immu-
ized mice per challenge group were infected with Pvs25DR3
40], and ﬁve mice infected with WT  P. berghei. Three days
ater, DFA was performed (Table 1a). Transmission blockade
as assessed as reduction in intensity and prevalence with
able 1a
valuation of TB activity induced by active immunization in DFA: Mice were immunize
ontained 10 immunized mice and was sub-divided into two groups, each containing ﬁve
erghei  2.34 (ﬁve mice), and used to assess transmission to mosquitoes via DFA. Each mo
ost  feed. Mean intensities and prevalence were calculated from all mice. (a) For both regim
umanely culled before DFA could be performed, resulting in only four mice per group. O
as  calculated by comparison to mice in the relevant immunized control groups. (b) Sig
ean  oocyst intensity) and the Fisher’s exact probability test (to examine the differenc
o  signiﬁcant changes in either intensity or prevalence were observed with any immun
vs25DR3. a = p < 0.05, Mann–Whitney U-test; b = p < 0.05, Fisher’s exact probability test.
FA  (a). Transmission following immunization, parasite challenge and DFA.
Challenge 
Regime 1: Pvs25-FhCMB Abisco-100 Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5
Regime 2: Pvs25-FhCMB Alhydrogel Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 4
Regime 3: Pvs25-ChAd63 - MVA  Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 4
Regime 4: Pvs25-ChAd63 - Pvs25-FhCMB -Abisco-100 Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5
Regime 5: LicKM-Abisco-100 Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5
Regime 6: LicKM-Alhydrogel Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5
Regime 7: GFP-ChAd63 - MVA Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5
Regime 8: GFP-ChAd63–LicKM-Abisco-100 Pb Pvs25DR3 challenge
Pb  2.34 challenge (n = 5orescence on ﬁxed, non-permeabilized parasites probed with anti-serum from each
inetes. Each panel shows an overlay of anti-Pvs25 signal (green) and DNA labeled
 in no signiﬁcant staining.
respect to the relevant non-Pvs25 control regimes (i.e. regime
1 is controlled by regime 5, regime 2 by regime 6, regime 3
by regime 7 and regime 4 by regime 8–Table 1b). For each
Pvs25-derived regime, a TB effect was observed following infec-
tion with P. berghei Pvs25DR3. Signiﬁcant reduction in intensity
was observed with regimes 1, 2 and 4, and signiﬁcant reduc-
tion in prevalence was  observed with all Pvs25-regimes. The
d with Pvs25-derived immunogens (or controls) as shown in Fig. 2. Each regime
 mice. Each group was then challenged with P. berghei Pvs25DR3 (5 mice) or WT P.
use was injected with 106 parasites. Mosquito midguts were dissected 10–12 days
es 2 and 4 with WT P. berghei challenge, mice developed cerebral malaria and were
verall transmission blockade (in terms of both infection intensity and prevalence)
niﬁcance was assessed using Mann–Whitney U-test (to examine the difference in
e in infection prevalence) (p < 0.05). Following challenge with WT P. berghei 2.34,
ization regime. Signiﬁcant inhibition was only observed following challenge with
 Table 1 Evaluation of transmission-blocking activity by active immunization and
Total
mosquitoes
Mean infection
intensity (±SEM)
Mean infection
prevalence
 (n = 5) n = 248 0.48 (0.18) 18.6%
) n = 171 40.8 (5.10) 96.8%
 (n = 5) n = 199 0.66 (0.29) 19.6%
) n = 135 40.7 (5.90) 95.3%
 (n = 5) n = 226 0.99 (0.39) 25.8%
) n = 148 45.1 (6.10) 93.6%
 (n = 5) n = 250 0.39 (0.17) 13.2%
) n = 142 42.8 (5.73) 98.0%
 (n = 5) n = 255 1.37 (0.40) 40.4%
) n = 129 43.7 (8.66) 90.8%
 (n = 5) n = 239 1.51 (0.47) 39.7%
) n = 175 40.2 (5.80) 88.6%
 (n = 5) n = 227 1.59 (0.54) 40.1%
) n = 167 38.0 (5.14) 94.0%
 (n = 5) n = 214 1.54 (0.51) 41.7%
) n = 134 41.8 (6.1) 93.3%
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Table  1b
Evaluation of transmission-blocking activity by immunization and DFA.
Challenge Mean change in infection intensity Mean change in prevalence
Regime 1: Pvs25-FhCMB Abisco-100 Pb Pvs25DR3 challenge (n = 5) 65.3% a 54.1% b
Pb 2.34 challenge (n = 5) 6.5% -6.6%
Regime 2: Pvs25-FhCMB Alhydrogel Pb Pvs25DR3 challenge (n = 5) 56.6% a 51.6% b
Pb 2.34 challenge (n = 5) -1.5% -7.6%
Regime 3: Pvs25-ChAd63 - MVA  Pb Pvs25DR3 challenge (n = 5) 38.0% 35.6% b
 = 5) 
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against recombinant Pvs25-FhCMB and r-Pvs25 in all immuniza-
tion regimes tested. As expected, a booster dose signiﬁcantly
increased the antibody titer against Pvs25-FhCMB in each
regime. The highest mean titer was observed with regime 1
Fig. 4. Ex vivo transmission-blocking efﬁcacy of serum generated by Pvs25-ChAd63
prime and Pvs25-FhCMB/Abisco-100 boost using in the DMFA. Pooled serum
sera from mice immunized with ChAd63u-Pvs25 and boosted with Pvs25-FhCMB
(regime 4) or mice immunized with ChAd63-GFP and boosted with LicKM (regime 8,
negative control) − were mixed 1:1 with heat-inactivated normal human AB serumPb 2.34 challenge (n
Regime 4: Pvs25-ChAd63 - Pvs25-FhCMB -Abisco-100 Pb Pvs25DR3 challe
Pb 2.34 challenge (n
ighest efﬁcacy in terms of both intensity and prevalence was
bserved following immunization with Pvs25-ChAd63, boosted
ith Pvs25F3E-LicKM/Abisco-100 (regime 4), where a mean
eduction in intensity/prevalence of 74.5%/68.3%, respectively
as achieved. Direct correlation between anti-Pvs25 titer and
ransmission-blocking efﬁcacy in individual mice was not observed
ith any signiﬁcance. As previously demonstrated [18,19,40], chal-
enge with WT  P. berghei gives rise to higher oocyst numbers than
bserved with Pvs25DR3. There was no detectable TB effect follow-
ng WT  P. berghei infection, indicating speciﬁc anti-Pvs25-derived
ransmission blockade.
.4. Evaluation of ex vivo TB activity (DMFA)
Serum collected from mice primed with Pvs25-ChAd63 and
oosted with Pvs25-FhCMB/Abisco-100 (regime 4), was  pooled and
valuated in DMFA. Results showed that the intensity and preva-
ence of oocyst infection on the mosquito midgut was  profoundly
educed in comparison with serum collected from the control group
mmunized with GFP-ChAd63 and boosted with LicKM/Abisco-100
regime 8) (Fig. 4). Over two replicate experiments, an overall 85.3%
eduction in infection intensity and a 25.6% reduction in prevalence
ere observed. Reduction in both intensity and prevalence were
igniﬁcant compared to control feeds (p = 0.0001 and p = 0.0033,
espectively).
. Discussion
Future control of malaria will require a multidimensional
pproach. Both the WHO  and the Malaria Eradication Research
genda have previously set as a core goal for any malaria vac-
ine program the need to reduce transmission and morbidity [43].
BVs are one potential component of this approach. Anti-malarial
B immunity can be mediated by antibodies that inhibit parasite
evelopment in the mosquito midgut [43–47].
We  have previously reported on the production of Pfs25 vari-
nts in N. benthamiana [29]. In that study, the presence of N-linked
lycans impaired the induction of TB activity by the recombinant
on-fusion version of Pfs25. To increase immunogenicity, Pfs25
acking N-glycosylation sites was fused to modiﬁed lichenase car-
ier molecule, LicKM [30]. The resulting protein induced high titers
ith long-lasting TB activity in mice. These results indicated the
tility of plant-derived Pfs25 as a TBV, and the importance of appro-
riate carrier molecules to enhance immunogenicity.
Here, in a parallel study, we describe the production and puriﬁ-
ation of soluble, Pvs25 recombinant antigen (Pvs25-FhCMB), using
 viral plant-based system. Similar to Pfs25, the Pvs25 sequence
ontains 22 cysteines, but unlike the Pfs25 sequence Pvs25 does not
ontain any putative N-linked glycosylation sites. Induction of func-
ional TB antibody responses against Pvs25 was assessed, following
mmunization with four different regimes: 1). Pvs25-FhCMB with
bisco-100 adjuvant; 2). Pvs25-FhCMB with Alhydrogel; 3). Viral
elivery of Pvs25 (Pvs25-ChAd63) with an MVA  boost (i.e. classical
deno-MVA ‘prime-boost’); and 4). A combination of adenoviral-18.7% 0.42%
 = 5) 74.5% a 68.3% b
-2.4% -4.9%
delivery (Pvs25-ChAd63) with a Pvs25-FhCMB recombinant pro-
tein boost. Ability of each regime to produce antibody capable of
recognizing native protein and exhibit TB efﬁcacy (in vivo and ex
vivo, with ﬁeld samples) was examined.
Immunization resulted in immunogen-speciﬁc responsesprepared from malaria-naive Thai donors. Diluted serum was then mixed with P.
vivax-infected blood cells (1:1 v/v ratio). Duplicate feeds were performed. Individ-
ual data points represent the number of oocysts found in individual mosquitoes 12
days post feed. Horizontal bars indicate mean intensity of infection, whilst error bars
indicate S.E.M. within individual samples.
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prime/boost with Pvs25-FhCMB/Abisco-100), whereas the low-
st anti-Pvs25-FhCMB end-point titers were elicited by regime 3
Pvs25-ChAd63/MVA). Recognizing that ELISAs against the Pvs25-
hCMB recombinant protein included signiﬁcant responses to
icKM (Fig. 3a outlines responses to Pvs25-FhCMB, comprising
ickM), we examined responses against Pvs25 speciﬁcally (Fig. 3b).
nder these conditions, the highest titer was observed with regime
 (Pvs25-ChAd63/Pvs25-FhCMB/Abisco-100), and the lowest with
egime 2 (Pvs25-FhCMB/Alhydrogel). However, when objectively
omparing differences in responses, it should be noted that no sig-
iﬁcant difference could be detected between regimes. It should be
tated that no detectable correlation between anti-Pvs25 titer and
ransmission-blocking efﬁcacy in individual mice was  observed,
upporting the hypothesis that antibody titer is not necessarily
he key parameter for predicting TBV efﬁcacy. It is likely that
ther additional qualitative changes, such as isotype switching and
fﬁnity maturation, will signiﬁcantly impact the biological activity
nd effector functions of any humoral immune response post-
mmunization. When examining the ability of serum to recognize
ative Pvs25 by IFA, sera from all regimes resulted in surface stain-
ng, corresponding to surface localization of Pvs25 [18,40]. Staining
as not observed with sera collected from mice immunized with
ontrol regimes (regimes 5, 6, 7 and 8), or when IFAs were con-
ucted on non-Pvs25-expressing (WT  2.34) ookinetes.
Although high titers are desirable, the functional effect of
mmunization on intensity and prevalence remains the key read-
ut to measure TBV effectiveness. These experiments employed
 proven transgenic model [18,19,40] to compare the ability of
mmunization to reduce oocyst development in the mosquito,
iving in vivo data to examine the comparative potency of
otential Pvs25-targeted TBVs. Every Pvs25-derived immunization
egime examined induced a TB response, with varying efﬁcacy. In
his study, immunization with the Pvs25-ChAd63/MVA platform
regime 3) led to the lowest observed TB effect (30.0% reduction
n intensity/35.6% reduction in prevalence). Substitution of MVA
oost at 8 weeks with 50 g of Pvs25-FhCMB plus Abisco-100 adju-
ant not only increased the end-point anti-Pvs25 antibody titer
against both Pvs25-FhCMB and r-Pvs25), but also increased the
fﬁcacy of the regime, to a 74.5% reduction in intensity/68.3% reduc-
ion in infection prevalence. The TB responses generated following
his regime are the highest induced within this comparative study,
learly demonstrating the attractiveness of combining adenoviral
elivery with a protein antigen. In the absence of adenoviral deliv-
ry, a potent response is still induced by regime 1, prime/boost with
vs25-FhCMB/Abisco-100, generating the second highest titers and
B responses (65.25% reduction in intensity/54.1% reduction in
revalence). When using Alhydrogel as adjuvant, a 56.58% reduc-
ion in intensity/56.82% reduction in prevalence was recorded.
igniﬁcant differences in antibody titers or TB efﬁcacy were not
ecorded when using Alhydrogel or Abisco-100 as an adjuvant with
vs25-FhCMB. None of the regimes generated a non-speciﬁc TB
ffect following challenge with P. berghei 2.34, suggesting a speciﬁc
esponse against Pvs25, and a lack of non-speciﬁc anti-P. berghei TB
ctivity. The TB potential of regime 4 (Pvs25-ChAd63/Pvs25-FhCMB
 the highest performing regime in the DFA), was further evaluated
y DMFA, resulting in a mean 85.3%/25.5% reduction in intensity
nd prevalence respectively, conﬁrming the ability of antibodies
enerated by this regime to block transmission in ﬁeld relevant
ssays. These results are broadly comparable to results observed
sing serum generated from i.m. delivery of adenoviral-vectored
vs25 in mice, described in Miyata et al. [39], where DMFA (car-
ied out in identical conditions to those described here) resulted in
eported reductions in oocyst intensity and prevalence of 84.1% and
1.7%, respectively. These promising results were achieved with an
mmunization of 50 g of Pvs25-FhCMB per mouse. Obviously, fur-
her dose ranging studies examining proportional immunizationse 34 (2016) 3252–3259
will need to be conducted before perusing product development in
human subjects.
Immunization with the regimes outlined here can be com-
pared to previously reported studies where the transgenic chimeric
parasite Pvs25DR3 was  used to determine in vivo potency of can-
didate TBVs. Pvs25 produced using an experimental baculovirus
expression system was  shown to induce a strong TB effect of
83.8% (intensity) and 88.4% (prevalence) in DFA following i.m.
immunization (mean control intensity of 2.16 oocysts/midgut)
[19]. These results are comparable to the 74.5% (intensity)/68.3%
(prevalence) reduction seen using regime 4 (Pvs25-ChAd63/Pvs25-
FhCMB boost), but are higher than the efﬁcacy observed with other
immunogens and adjuvants used within this study. Crucially, the
Baculovirus-Dual-Expression system (BDES) described in Blagbor-
ough et al. [19] is not currently approved for use in human trials,
whereas both adenoviral and Nicotiana-based expression systems
have an extensive track record for the production of antigens to be
used in human trials. Additionally, a similar approach has previ-
ously been taken to examine the efﬁcacy of adenoviral anti-Pfs25
(P. falciparum homolog of Pvs25) vaccines [38]. TB efﬁcacy was
assessed using a homologous chimeric parasite (Pfs25DR3) gen-
erated identically to Pvs25DR3. Cohorts of mice were immunized
with AdHu5/MVA Pfs25 in a heterologous prime boost regime, and
subjected to DFA. A 67% reduction in intensity and a 28% reduction
in prevalence were reported. This translated to a 96% reduction in
intensity and 78% reduction in prevalence at sera dilutions of one
in ﬁve in SMFA. The ability of the plant-derived antigens tested in
this study to induce in vivo and ex vivo efﬁcacy similar to previously
examined P25-based immunogens lends weight to their continued
development within the TBV pipeline.
This study gives a clear indication as to the value of Nicotiana
and adenoviral-derived immunogens to induce a TB response. The
efﬁcient plant-based production of Pvs25, generation of high titers
and induction of a TB response demonstrates the capability of these
approaches to produce anti-malarial TBVs. Crucially, this study also
demonstrates that combining this with other vaccine platforms
(e.g. adenoviral delivery) can elicit maximal potency.
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